Holen Sie sich die Stockscreener-App
1.82
1.11%
0.02
Handel nachbörslich:
1.78
-0.04
-2.20%
Schlusskurs vom Vortag:
$1.80
Offen:
$1.78
24-Stunden-Volumen:
1.26M
Relative Volume:
0.60
Marktkapitalisierung:
$297.33M
Einnahmen:
$12.87M
Nettoeinkommen (Verlust:
$-114.34M
KGV:
-2.105
EPS:
-0.8646
Netto-Cashflow:
$-79.23M
1W Leistung:
+2.25%
1M Leistung:
-5.70%
6M Leistung:
-3.19%
1J Leistung:
-25.71%
1-Tages-Spanne:
$1.755
$1.845
1-Wochen-Bereich:
$1.70
$1.98
52-Wochen-Spanne:
$1.05
$4.32
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Vergleichen Sie TSHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
1.82 | 297.33M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
What is Taysha Gene Therapies Inc (TSHA) Stock Return on Shareholders’ Capital? - Sete News
Taysha Gene Therapies’ (TSHA) Overweight Rating Reaffirmed at Cantor Fitzgerald - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Receives Market Outperform Rating from JMP Securities - Defense World
Understanding the Risks of Investing in Taysha Gene Therapies Inc (TSHA) - knoxdaily.com
Examining TSHA’s book value per share for the latest quarter - uspostnews.com
Taysha Gene Therapies Inc (NASDAQ: TSHA) Prices Could Soar To Much Higher Levels In Coming Months - Marketing Sentinel
Geode Capital Management LLC Has $6.18 Million Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc (TSHA) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Keeping an Eye on Taysha Gene Therapies Inc (TSHA) After Insider Trading Activity - knoxdaily.com
Taysha Gene Therapies Inc [TSHA] stock Initiated by BMO Capital Markets analyst, price target now $5 - dbtnews.com
Discover Fractyl Health And 2 More Promising Penny Stocks - simplywall.st
Anchoring Your Portfolio: Is TSHA Stock a Safe Harbor? - investchronicle.com
What is going on with Taysha Gene Therapies Inc? Sentiment Analysis - uspostnews.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by JPMorgan Chase & Co. - Defense World
Vanguard Group Inc. Raises Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity - Seeking Alpha
Wellington Management Group LLP Raises Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Commonwealth Equity Services LLC Purchases 31,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of “Buy” from Brokerages - The AM Reporter
AskBio Elects Dr. Laura Sepp-Lorenzino Independent Member of Board of Directors - The Manila Times
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Target Price from Brokerages - Defense World
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Expands Team: 822,000 Stock Options Awarded in Strategic Growth Move - Stock Titan
At $1.32 Price, Taysha Gene Therapies Inc (TSHA) Is Sitting And Waiting - stocksregister.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges By Investing.com - Investing.com South Africa
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges - Investing.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 111,989 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? - Insider Monkey
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Taysha Gene Therapies (TSHA) Projected to Post Earnings on Tuesday - The AM Reporter
Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63 - Defense World
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment By Investing.com - Investing.com South Africa
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment - Investing.com Australia
Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday - Defense World
Taysha's Latest Stock Option Grants: Key Details for Institutional Investors - StockTitan
Alexandria Real Estate Equities, Inc. Elects Claire Aldridge, PhD, to Board of Directors - The Malaysian Reserve
Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Yahoo Finance
TSHA FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Chardan Capital Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies’ Positive Earnings Call Highlights - TipRanks
Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position - TipRanks
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Taysha Gene Therapies Reports 2024 Financial Results - TipRanks
Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability - TipRanks
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
2.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):